Head-to-head · WeighScore
Invigor Medical vs NewSelf
The verdict
Invigor Medical takes it — 86/100 to 85/100, but only just.
Invigor Medical grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. An established pharmacy operator with steady mid-market pricing and a broad catalog. NewSelf is close behind and may still be the better fit — see the factor split below.
Partner links are labeled — we may earn a commission at no cost to you. It never changes the grade.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Invigor Medical | NewSelf |
|---|---|---|
| WeighScore | 86/100 | 85/100 |
| Grade | B | B |
| Scorecard rank | #5 | #8 |
| Semaglutide | $199/mo | $100/mo |
| Tirzepatide | $339/mo | $144/mo |
| Coverage | Not disclosed | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| Relationship | Partner | Editorial |
Graded #5 · B
Strengths
- Mid-market pricing on both molecules
- Long-running operator
Where it loses points
- No explicit states list
- Compounded only
Graded #8 · B
Strengths
- $100 sema / $144 tirz
- All 50 states, LegitScript-verified
- Both molecules
Where it loses points
- Injection-only
- Labs/monitoring detail sparse
- Limited brand history
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.